Vandergrift M, Kanavos P
London School of Economics and Political Science, UK.
Health Policy. 1997 Sep;41(3):241-60. doi: 10.1016/s0168-8510(97)00036-5.
This paper analyses the trade-off between health policy and industrial policy objectives in the field of pharmaceuticals in the Canadian policy setting. In Canada pharmaceutical regulation is organized in two tiers. The federal government is responsible for the conduct of industrial policy for the pharmaceutical sector, including the patenting of new molecular entities, the registration and approval of pharmaceutical products, and the pricing of new products. At the province level, policy-makers are responsible for the reimbursement of the cost of medicines; the methodologies implemented for this purpose may be geared towards meeting the objective of cost containment within tight health budgets rather than addressing industrial policy objectives and, thereby, supporting the pharmaceutical industry. The reimbursement methodologies implemented may also be related with the strength of pharmaceutical presence in each province. The paper provides evidence from two such provinces, British Columbia and Ontario, and contrasts pharmaceutical policy-making at the provincial level with that at the federal level.
本文分析了加拿大政策背景下制药领域卫生政策与产业政策目标之间的权衡。在加拿大，药品监管分为两个层级。联邦政府负责制药行业的产业政策实施，包括新分子实体的专利申请、药品注册与审批以及新产品定价。在省级层面，政策制定者负责药品费用报销；为此实施的方法可能旨在实现严格卫生预算内的成本控制目标，而非解决产业政策目标，从而支持制药行业。所实施的报销方法也可能与每个省份制药企业的实力相关。本文提供了来自不列颠哥伦比亚省和安大略省这两个省份的证据，并将省级层面的药品政策制定与联邦层面的进行了对比。
